Supplements and Heart Rhythm: The QT Safety Map

Most supplement safety questions are noisy: small studies, weak signals, contradictory meta-analyses. Cardiac repolarization is different. The QT interval is measurable on a 12-lead ECG, the hERG ion channel has a published mechanism, and the agencies and industry bodies that track adverse events (FDA, EMA, and the trade association Council for Responsible Nutrition's reporting framework) have decades of pharmacovigilance data on which compounds trigger which kinds of cardiac events.

That makes this one of the few areas where a supplement-safety guide can be honest, specific, and useful. This article walks the named botanicals that show real hERG or QT signal in the literature, the drug-supplement combinations that drive most reported events, and the cardioprotective compounds whose evidence base actually holds up under scrutiny.

For prescription-side decisions about QT-prolonging drugs (azithromycin, ondansetron, methadone, citalopram, the antifungal-azole family, several antipsychotics), see our sister site OmniRx's clinical decision guide on ibogaine and cardiac safety, which covers the underlying QT pharmacology in clinical-decision-support depth.

Why QT interval and hERG matter

The QT interval on an electrocardiogram measures the time it takes a ventricular cell to depolarize, contract, and re-polarize so it can fire again. When that interval lengthens, the chance of a chaotic re-entry rhythm called torsades de pointes (TdP) goes up. TdP can degenerate into ventricular fibrillation, which is a cardiac arrest mechanism (FDA E14).

At the molecular level, the most common reason the QT interval lengthens pharmacologically is blockade of the rapid delayed-rectifier potassium channel, abbreviated I_Kr and encoded by the hERG (KCNH2) gene (Tay et al., 2016). Drugs and natural compounds that bind hERG with high affinity prolong repolarization. The U.S. FDA's E14 guideline (harmonized with ICH, adopted at ICH Step 4 in May 2005 and issued as FDA guidance in October 2005; FDA) is the regulatory framework drugmakers use to assess QT liability before approval, and the hERG-binding assay is now a routine in-vitro screen in pharmaceutical and toxicology development.

Supplements do not go through E14. They are regulated under DSHEA (Dietary Supplement Health and Education Act, 1994), which means manufacturers do not need to demonstrate cardiac safety before sale: unlike drugs, supplements are not approved by the FDA before they are sold (NCCIH). The pharmacovigilance signal comes after, through FDA's adverse event reports for foods and supplements (the former CFSAN Adverse Event Reporting System, CAERS, now the Human Foods Complaint System under FDA's Human Foods Program, FDA, which FDA is folding into its agency-wide Adverse Event Monitoring System launched in March 2026, FDA), case reports in the peer-reviewed literature, and CRN industry reports. The result is uneven coverage: some botanicals have decades of pharmacovigilance data, others have essentially none.

As an Amazon Associate I earn from qualifying purchases.

Botanicals with documented QT or hERG signal

The compounds below are the ones with clinical case reports, hERG-binding data, or both. This is not a complete list; absence from this list is not safety. It is a list of names where the published evidence is concrete enough that a reasonable cardiology consult would mention them.

Licorice (Glycyrrhiza glabra), Risk: Real and dose-dependent

Licorice is the supplement-safety question where the evidence is least ambiguous. Glycyrrhizin's metabolites inhibit type 2 11-β-hydroxysteroid dehydrogenase in the kidney, which leaves cortisol free to act on mineralocorticoid receptors (Yoshino et al., 2021). The downstream effect is potassium loss (hypokalemia), and hypokalemia in turn prolongs the QT interval and lowers the TdP threshold; case reports document licorice-induced hypokalemia ending in torsades (Molina-Lopez et al., 2023), and NCCIH lists irregular heartbeat and cardiac arrest among glycyrrhizin's serious effects (NCCIH).

The WHO/FAO Joint Expert Committee on Food Additives judged that about 100 mg of glycyrrhizin a day would be unlikely to cause adverse effects in most adults, while warning that highly susceptible people can react below that figure (WHO JECFA). A single licorice tea bag can deliver 30 to 50 mg; licorice herbal tea averaged 126 mg per litre in the intake data JECFA reviewed, roughly 30 mg a mug. Black licorice candy (genuine, glycyrrhizin-containing, not anise-flavored) can deliver several hundred mg per serving. An FDA consumer update (2017, since retired from fda.gov) warned that if you are 40 or older, eating 2 ounces of black licorice a day for at least two weeks could land you in the hospital with an irregular heart rhythm (FDA, archived). The mechanism is chiefly potassium-depletion-mediated QT prolongation, not direct hERG block, and NCCIH notes that even small amounts of glycyrrhizin have been linked to severe adverse effects in people with hypertension or heart or kidney conditions (NCCIH).

Deglycyrrhizinated licorice (DGL) products have the glycyrrhizin removed and do not carry the glycyrrhizin risk; NCCIH considers them possibly safe for up to 4 months (NCCIH). If you use licorice for GI or adrenal support, DGL is the safer form, and if you take a diuretic or a QT-prolonging prescription, clear any licorice product with your prescriber first.

Ephedra (Ephedra sinica, ma huang), Banned in the U.S. for cause

Ephedra-containing supplements were removed from the U.S. market by FDA in 2004 because of serious safety risks; even in relatively low doses and short-term use, ephedra was linked to high blood pressure, heart attack, seizure, and stroke (NCCIH). Ephedrine alkaloids drive sympathetic-nervous-system activation, which raises heart rate, blood pressure, and contributes to ischemic and arrhythmic events. Ephedra remains available outside the U.S. and through illicit channels. If you encounter it abroad or as an undeclared adulterant in a weight-loss or performance product, treat it as contraindicated with any pre-existing cardiac condition.

Bitter orange (Citrus aurantium / synephrine), The ephedra successor

After ephedra was banned, the supplement industry shifted to bitter-orange-derived synephrine for many of the same use cases (weight loss, energy, athletic stim). Its main active compound, p-synephrine, is structurally similar to ephedrine, though NCCIH notes it has different pharmacologic properties. Published case reports describe abnormal heart rhythms, heart attacks, and strokes in people who had taken bitter-orange products, particularly when combined with caffeine, but most of those products contained multiple ingredients, so NCCIH calls bitter orange's own role unclear (NCCIH). The literature is smaller than for ephedra and conclusions are less firm, but the mechanism overlaps.

If you take a pre-workout or fat-burner blend, check the label for Citrus aurantium, synephrine, p-synephrine, or m-synephrine. The label is not a guarantee: when FDA researchers analyzed 59 bitter orange supplements, six were adulterated with synthetic amines (methylsynephrine or isopropyloctopamine) that are not legal dietary ingredients in the United States (NCCIH).

Yohimbine (Pausinystalia yohimbe), α2-blockade with cardiac visibility

Yohimbine is an α2-adrenergic antagonist. Removing the inhibitory α2 receptor's brake on norepinephrine release produces a sympathetic-tone surge that can cause hypertension, tachycardia, panic-like symptoms, and in case-report literature, ventricular arrhythmias; NCCIH lists cardiac arrhythmia, blood pressure problems, heart attacks, and seizures among yohimbine's associated harms (NCCIH). The effect is dose-dependent. Yohimbine is sold as an erectile-dysfunction and weight-loss supplement at retail (though marketing an over-the-counter yohimbine product as an erectile-dysfunction treatment without FDA approval is illegal); an analysis of 49 U.S. brands found anywhere from none to 12.1 mg of yohimbine per serving, and only 11 stated an amount on the label (Cohen et al., 2016), but pre-workout blends can stack it with caffeine and synephrine in ways that compound the cardiovascular load.

NCCIH adds a drug-interaction line worth knowing: do not use yohimbe if you take monoamine oxidase inhibitors or tricyclic antidepressants, and talk with your health care provider before combining it with any other medicine (NCCIH).

Kratom (Mitragyna speciosa), hERG block at higher doses

Kratom alkaloids (mitragynine and several related alkaloids) inhibited hERG channels in lab studies at low micromolar concentrations, and mitragynine prolonged repolarization and induced arrhythmia in human stem-cell-derived heart cells (Lu et al., 2014; Tay et al., 2016). The clinical translation is uncertain: in the rare deaths associated with kratom, FDA notes it was usually used in combination with other drugs and its contribution is unclear (FDA), and the published cardiac case reports likewise tend to involve polypharmacy (kratom + opioids, kratom + stimulants) rather than kratom monotherapy. FDA's position is that kratom is not lawfully marketed in the U.S. as a dietary supplement, it keeps kratom on Import Alert 54-15 (most recently published in August 2026) (FDA), and as of October 2026 the DEA has published a notice of intent to temporarily place 7-hydroxymitragynine above a specified threshold in Schedule I (Federal Register). If you use kratom and are also on a QT-prolonging prescription, this is a combination worth a cardiology conversation.

Hawthorn (Crataegus spp.), Mostly favorable but worth a note

Hawthorn is a venerable cardiotonic with a European Medicines Agency herbal monograph (HMPC), and a telling one: on the basis of long-standing use, the HMPC accepts hawthorn leaf and flower for symptoms of temporary heart complaints related to nervousness, such as palpitations, after a doctor has excluded serious conditions (EMA). The heart failure evidence is conflicting, as NCCIH puts it (NCCIH): the large SPICE trial of the extract WS 1442 in NYHA Class II-III patients found no significant effect on its primary endpoint, though it was safe alongside optimal heart failure medication (Holubarsch et al., 2008). The relevant caveat for this article: hawthorn extract blocks repolarizing potassium currents and prolongs action potential duration in guinea pig heart cells (Müller et al., 1999), though adverse events in SPICE were comparable to placebo at 900 mg a day. The interaction risk is greater for hawthorn + digoxin than for hawthorn-driven QT events: lab data suggest hawthorn may interfere with digoxin's action, and Memorial Sloan Kettering advises that people on heart failure medicines use hawthorn only under close physician monitoring (MSKCC).

Grapefruit (technically not a supplement), But it lives here

Grapefruit and grapefruit-juice furanocoumarins inhibit intestinal CYP3A4 enzymes. The list of QT-prolonging drugs whose serum concentrations rise with concurrent grapefruit intake includes amiodarone (FDA), dronedarone, whose label tells patients to avoid grapefruit juice (Multaq label, DailyMed), erythromycin (Kanazawa et al., 2001), and the antimalarial halofantrine, where grapefruit juice raised the drug's peak QTc prolongation from 17 ms to 31 ms (Charbit et al., 2002). Grapefruit also raises several statins, which matters for muscle and liver rather than rhythm, and its effect on the azole antifungals is inconsistent: it lowered itraconazole capsule exposure by 43% in one study (Penzak et al., 1999). Grapefruit is not only a bystander: in a thorough QT study run to drug-industry standards, 2 L of grapefruit juice prolonged the QTc of healthy volunteers by 14.0 ms, comparable to the antibiotic moxifloxacin, and by 21.8 ms in people with congenital long QT syndrome (Chorin et al., 2019), most likely through hERG block by its flavonoid naringenin (Zitron et al., 2005). Its bigger effect, though, is that it raises the blood level of the drugs that do. This is the most under-appreciated cardiac-pharmacology interaction in dietary intake.

Pomelo, Seville orange and tangelo can have the same effect as grapefruit juice, according to the FDA, which advises asking your doctor or pharmacist whether your specific drug is affected (FDA). Sweet orange does not appear to: in the halofantrine study, orange juice made no significant difference compared with water (Charbit et al., 2002).

Drug-supplement combinations that drive most reported events

When FDA's adverse event reports (CAERS, now HFCS) or peer-reviewed case reports describe a supplement-related QT event, the mechanism is rarely supplement-only. It is usually a stack: a QT-prolonging prescription drug, a supplement that depletes potassium or magnesium, and sometimes a metabolic perturbation (vomiting, diarrhea, dehydration) that lowers serum potassium acutely.

Supplements with a defensible cardioprotective signal

The flip side of supplement cardiac safety is the small set of compounds where the evidence for cardiovascular benefit is robust enough to take seriously. None of these are magic. All have plausible mechanisms and meta-analytic evidence beyond a single RCT.

Omega-3 (EPA + DHA from marine sources), Evidence: 7.5/10

The REDUCE-IT trial (2018, NEJM) showed icosapent ethyl 4 g/day reduced major adverse cardiovascular events in statin-treated patients with elevated triglycerides, 17.2% versus 22.0% over a median 4.9 years (Bhatt et al., 2019). Earlier trials with mixed EPA/DHA were less consistent. The mechanistic story includes mild membrane-stabilizing effects, anti-inflammatory action, and triglyceride lowering. The relevant note for this article: the rhythm signal that has actually turned up for omega-3 is atrial fibrillation, not QT. In REDUCE-IT, 3.1% of the icosapent ethyl group versus 2.1% on placebo were hospitalized for atrial fibrillation or flutter (Bhatt et al., 2019), the prescription label carries that warning (Vascepa label, DailyMed), and a meta-analysis of seven outcome trials found a 25% higher atrial fibrillation risk overall, steeper in trials above 1 g/day (Gencer et al., 2021); the NIH describes the increase at 4 g/day as slight (NIH ODS). On QT itself, higher fish and marine omega-3 intake has tracked with a lower likelihood of a prolonged QT (Mozaffarian et al., 2006). Most experts still treat omega-3 as net-favorable for cardiac safety in indicated populations, but anyone with a history of atrial fibrillation should settle the dose with their clinician.

Magnesium, Evidence: 8.0/10 (as electrolyte, not as cure)

Magnesium is the electrolyte that most reliably stops torsades, even though it often does not shorten the prolonged QT interval itself: in the classic series, a single 2 g intravenous bolus abolished torsades in 9 of 12 patients within minutes, with no significant change in the QT (Tzivoni et al., 1988). Intravenous magnesium is the first-line treatment for acute torsades. Oral magnesium supplementation makes sense in chronic low-magnesium states (chronic diuretic use, alcohol use disorder, malabsorption): the NIH notes that long-term loop and thiazide diuretics can increase magnesium loss and lead to depletion (NIH ODS). Most adults eating a varied diet do not need supplemental magnesium for cardiac protection. Those on diuretics or with documented hypomagnesemia do.

Keep the dose inside the limit: the NIH sets the Tolerable Upper Intake Level for supplemental magnesium at 350 mg a day for adults, and very high doses can themselves cause irregular heartbeat and cardiac arrest (NIH ODS). On a page about heart rhythm, more is not better.

CoQ10 (ubiquinone / ubiquinol), Evidence: 6.0/10

The Q-SYMBIO trial (2014) showed CoQ10 100 mg three times daily, added to standard therapy in 420 patients with moderate to severe chronic heart failure, cut major adverse cardiovascular events (15% versus 26%) and all-cause mortality (10% versus 18%) over two years (Mortensen et al., 2014). Subsequent evidence has been mixed, and NCCIH still calls the heart failure research inconclusive (NCCIH). The mechanism is mitochondrial-respiratory-chain support. CoQ10 is also used to mitigate statin-associated muscle symptoms, where NCCIH says the overall evidence does not support a benefit, though the risk profile is low.

One interaction matters for cardiac patients in particular: NCCIH notes that CoQ10 may interact with the blood thinner warfarin, so anyone on warfarin should start or stop it only with their prescriber's knowledge (NCCIH).

Taurine, Evidence: 5.5/10

Taurine is included in the energy-drink ingredient deck for branding reasons, not for the cardiac evidence; the clinically interesting work on taurine is in congestive heart failure (Japanese investigators have run several small trials showing benefit, including a 14-patient double-blind crossover trial in which taurine improved NYHA functional class, Azuma et al., 1985). The case for taurine supplementation in healthy adults is thin. The case for taurine in late-stage CHF is plausible but not first-line.

How to read the safety literature when your supplement is not on this list

This article names the compounds with the clearest evidence. Most supplement-cardiac questions you will encounter in practice involve botanicals that have either no published cardiac literature, or only one or two case reports of uncertain causality. Here is the decision framework we use editorially:

1. Check FDA's adverse event data. Search the supplement name in the Human Foods Complaint System files (formerly CAERS) or FDA's new Adverse Event Monitoring System and look at the cardiac event categories. Most reporting is voluntary and FDA notes a report does not always show the product caused the event, so absence is not safety, but presence is signal.
2. Check Natural Medicines or similar curated databases for hERG / QT entries. Natural Medicines, Memorial Sloan Kettering's About Herbs database, and the European Medicines Agency HMPC monographs are the three sources we cross-reference editorially. A single source with a positive signal is worth a follow-up; concurrence across two is strong.
3. Read the case reports, not just the meta-analyses. Meta-analyses average out rare events. The literature on supplement-associated cardiac events is dominated by case reports, and the pattern of polypharmacy in those case reports is the actionable information.
4. If you are on a QT-prolonging prescription, default to caution. The CredibleMeds list (crediblemeds.org) is the published reference for QT-prolonging prescription drugs, maintained by AZCERT, the independent non-profit that grew out of the University of Arizona's Center for Education and Research on Therapeutics (CredibleMeds). If your prescription is on the Known Risk list, treat any new supplement as something to clear with the prescribing clinician.

A practical decision frame

If we had to compress this into a four-line decision frame:

• If you have a known cardiac history (long-QT syndrome, prior arrhythmia, heart failure, structural disease) and are considering any new supplement: confirm with your cardiologist that the supplement is not on the CredibleMeds-adjacent literature.
• If you are on a QT-prolonging prescription: avoid licorice, ephedra, bitter orange, yohimbine, and high-dose kratom. Default to caution on grapefruit-containing beverages.
• If you are healthy and on no QT-active medications: the named botanicals above are still worth knowing, but you have wider latitude.
• If you supplement for cardiovascular protection: omega-3, magnesium (when indicated), and CoQ10 (in CHF) are the three compounds with the best evidence. The rest is marketing.

FAQs

Sources

1. U.S. Food and Drug Administration. Guidance for Industry E14: Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Accessed 19 October 2026.
2. Tay YL et al. Mitragynine and its potential blocking effects on specific cardiac potassium channels. Toxicol Appl Pharmacol, 2016. Accessed 19 October 2026.
3. Lu J et al. Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes. PLoS One, 2014. Accessed 19 October 2026.
4. U.S. Food and Drug Administration. Human Foods Complaint System (HFCS). Accessed 19 October 2026.
5. U.S. Food and Drug Administration. FDA Launches New Adverse Event Look-Up Tool (11 March 2026). Accessed 19 October 2026.
6. NIH National Center for Complementary and Integrative Health. Licorice Root. Accessed 19 October 2026.
7. Yoshino T et al. Clinical Risk Factors of Licorice-Induced Pseudoaldosteronism Based on Glycyrrhizin-Metabolite Concentrations. Front Nutr, 2021. Accessed 19 October 2026.
8. Molina-Lopez V et al. Close Call From a Sweet Twist: A Case of Licorice-Induced Torsades De Pointes. Cureus, 2023. Accessed 19 October 2026.
9. WHO/FAO Joint Expert Committee on Food Additives. Glycyrrhizinic acid (2005 evaluation). Accessed 19 October 2026.
10. U.S. Food and Drug Administration. Black Licorice: Trick or Treat? (2017 consumer update, archived copy). Accessed 19 October 2026.
11. NIH National Center for Complementary and Integrative Health. Ephedra. Accessed 19 October 2026.
12. NIH National Center for Complementary and Integrative Health. Bitter Orange. Accessed 19 October 2026.
13. NIH National Center for Complementary and Integrative Health. Yohimbe. Accessed 19 October 2026.
14. Cohen PA et al. Pharmaceutical quantities of yohimbine found in dietary supplements in the USA. Drug Test Anal, 2016. Accessed 19 October 2026.
15. U.S. Food and Drug Administration. FDA and Kratom. Accessed 19 October 2026.
16. U.S. Food and Drug Administration. Import Alert 54-15. Accessed 19 October 2026.
17. Drug Enforcement Administration. Notice of intent: temporary placement of 7-hydroxymitragynine and mitragynine pseudoindoxyl above a specified threshold in Schedule I (Federal Register, 14 October 2026). Accessed 19 October 2026.
18. European Medicines Agency. Hawthorn leaf and flower (Crataegi folium cum flore), HMPC summary. Accessed 19 October 2026.
19. NIH National Center for Complementary and Integrative Health. Hawthorn. Accessed 19 October 2026.
20. Holubarsch CJ et al. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail, 2008. Accessed 19 October 2026.
21. Müller A et al. Crataegus extract blocks potassium currents in guinea pig ventricular cardiac myocytes. Planta Med, 1999. Accessed 19 October 2026.
22. Memorial Sloan Kettering Cancer Center. About Herbs: Hawthorn. Accessed 19 October 2026.
23. Chorin E et al. Grapefruit juice prolongs the QT interval of healthy volunteers and patients with long QT syndrome. Heart Rhythm, 2019. Accessed 19 October 2026.
24. Zitron E et al. QTc prolongation by grapefruit juice and its potential pharmacological basis: HERG channel blockade by flavonoids. Circulation, 2005. Accessed 19 October 2026.
25. U.S. Food and Drug Administration. Grapefruit Juice and Some Drugs Don't Mix. Accessed 19 October 2026.
26. NLM DailyMed. Multaq (dronedarone) prescribing information. Accessed 19 October 2026.
27. Kanazawa S et al. The effects of grapefruit juice on the pharmacokinetics of erythromycin. Eur J Clin Pharmacol, 2001. Accessed 19 October 2026.
28. Charbit B et al. Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther, 2002. Accessed 19 October 2026.
29. Penzak SR et al. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monit, 1999. Accessed 19 October 2026.
30. Cheng KL et al. Effect of grapefruit juice on clarithromycin pharmacokinetics. Antimicrob Agents Chemother, 1998. Accessed 19 October 2026.
31. U.S. Food and Drug Administration. Celexa (citalopram) prescribing information, 2024. Accessed 19 October 2026.
32. NIH National Center for Complementary and Integrative Health. St. John's Wort. Accessed 19 October 2026.
33. NLM DailyMed. Methadone hydrochloride prescribing information. Accessed 19 October 2026.
34. NLM DailyMed. Ondansetron prescribing information. Accessed 19 October 2026.
35. NLM DailyMed. Haloperidol prescribing information. Accessed 19 October 2026.
36. Bhatt DL et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). N Engl J Med, 2019. Accessed 19 October 2026.
37. NLM DailyMed. Vascepa (icosapent ethyl) prescribing information. Accessed 19 October 2026.
38. Gencer B et al. Effect of Long-Term Marine Omega-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation. Circulation, 2021. Accessed 19 October 2026.
39. NIH Office of Dietary Supplements. Omega-3 Fatty Acids, Health Professional Fact Sheet. Accessed 19 October 2026.
40. Mozaffarian D et al. Dietary fish and n-3 fatty acid intake and cardiac electrocardiographic parameters in humans. J Am Coll Cardiol, 2006. Accessed 19 October 2026.
41. Tzivoni D et al. Treatment of torsade de pointes with magnesium sulfate. Circulation, 1988. Accessed 19 October 2026.
42. NIH Office of Dietary Supplements. Magnesium, Health Professional Fact Sheet. Accessed 19 October 2026.
43. Mortensen SA et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO. JACC Heart Fail, 2014. Accessed 19 October 2026.
44. NIH National Center for Complementary and Integrative Health. Coenzyme Q10. Accessed 19 October 2026.
45. Azuma J et al. Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. Clin Cardiol, 1985. Accessed 19 October 2026.
46. AZCERT. About CredibleMeds. Accessed 19 October 2026.
47. NIH National Center for Complementary and Integrative Health. Ashwagandha. Accessed 19 October 2026.
48. U.S. Food and Drug Administration. Spilling the Beans: How Much Caffeine is Too Much? Accessed 19 October 2026.
49. Fletcher EA et al. Randomized Controlled Trial of High-Volume Energy Drink Versus Caffeine Consumption on ECG and Hemodynamic Parameters. J Am Heart Assoc, 2017. Accessed 19 October 2026.
50. Shah SA et al. Impact of High Volume Energy Drink Consumption on Electrocardiographic and Blood Pressure Parameters: A Randomized Trial. J Am Heart Assoc, 2019. Accessed 19 October 2026.